Timothy Chan, MD, PhD, has been appointed Director of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic. Dr. Chan will lead the new center to bring together multidisciplinary experts from across the Cleveland Clinic enterprise to advance research and treatment related to immuno-oncology.
Timothy Chan, MD, PhD
Dr. Chan will also collaborate with experts in the new Center for Global and Emerging Pathogens Research, which is focused on broadening understanding of immunology and microbial pathogenesis with the goal of improving treatment of a variety of diseases, including virus-induced cancers.
“Immunotherapy is the future of research in cancer and various other diseases, and Cleveland Clinic has made it a priority by establishing this new center,” said Serpil Erzurum, MD, Chair of Cleveland Clinic’s Lerner Research Institute.
Dr. Chan joins Cleveland Clinic from Memorial Sloan Kettering Cancer Center and Weill Cornell School of Medicine, where he led the Immunogenomics and Precision Oncology Platform and was a tenured professor, the PaineWebber Chair, and the Translational Oncology Division Chair. He is an expert in precision immuno-oncology and a pioneer in using genomics to determine which patients will respond best to certain types of immunotherapies.
Brian Bolwell, MD, Chairman of Taussig Cancer Institute, Cleveland Clinic Cancer Center, commented on the appointment: “The addition of Dr. Chan, a pioneer in cancer genomics, and the new center’s focus on research and clinical trials will strengthen our ability to provide advanced treatment options for our patients.”
Dr. Chan joins the leadership of the National Center for Regenerative Medicine of Case Western Reserve University. He is also on staff in the Genomic Medicine Institute of the Lerner Research Institute and the Department of Radiation Oncology of the Taussig Cancer Institute.
Dr. Chan earned his MD and PhD degrees in genetics from Johns Hopkins University, where he also completed a residency in radiation oncology and a postdoctoral fellowship in the Division of Tumor Biology.
